List view / Grid view
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and bring innovations to patients faster.
In this second interview of the series, Andreas Kolleger, Head of GenAI Innovation at Neo4j, discusses how knowledge graphs and AI are transforming scientific discovery and improving life sciences workflows.
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM.
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we…
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
